Biology of Blood and Marrow Transplantation
Volume 13, Issue 7 , Pages 778-789 , July 2007

Utility of Single versus Tandem Autotransplants for Advanced Testes/Germ Cell Cancer: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis

  • Hillard M. Lazarus

      Affiliations

    • University Hospitals of Cleveland, Cleveland, Ohio
    • Corresponding Author InformationCorrespondence and reprint requests: Hillard M. Lazarus, MD, Department of Medicine, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106.
    • ,
  • Patrick J. Stiff

      Affiliations

    • Loyola University Medical Center, Maywood, Illinois
    • ,
  • Jeanette Carreras

      Affiliations

    • The Solid Tumor Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), Health Policy Institute, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Brent R. Logan

      Affiliations

    • The Solid Tumor Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), Health Policy Institute, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Luke Akard

      Affiliations

    • Indiana Blood & Marrow Transplantation, Beach Grove, Indiana
    • ,
  • Brian J. Bolwell

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Richard W. Childs

      Affiliations

    • National Institutes of Hematology, Bethesda, Maryland
    • ,
  • Robert Peter Gale

      Affiliations

    • Center for Advanced Studies in Leukemia
    • ,
  • John P. Klein

      Affiliations

    • The Solid Tumor Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), Health Policy Institute, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Michael C. Lill

      Affiliations

    • Cedars Sinai Medical Center, Los Angeles, California
    • ,
  • Waleska S. Pérez

      Affiliations

    • The Solid Tumor Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), Health Policy Institute, Medical College of Wisconsin, Milwaukee, Wisconsin
    • ,
  • Edward A. Stadtmauer

      Affiliations

    • University of Pennsylvania Hospital, Philadelphia, Pennsylvania
    • ,
  • J. Douglas Rizzo

      Affiliations

    • The Solid Tumor Working Committee of the Center for International Blood and Marrow Transplant Research (CIBMTR), Health Policy Institute, Medical College of Wisconsin, Milwaukee, Wisconsin

Received 25 January 2007 ,Accepted 28 February 2007.

References 

  1. Einhorn EH. Testicular cancer: an oncological success story. Clin Cancer Res. 1997;3:2630–2632
  2. Sonneveld DJ, Hoekstra HJ, van der Graaf WT, et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer. 2001;91:1304–1315
  3. Loehrer PJ, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998;16:2500–2504
  4. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol. 1997;15:594–603
  5. Hartmann JT, Nichols CR, Droz JP, et al. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol. 2002;13:1017–1028
  6. Nichols CR, Williams SD, Loehrer PJ, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol. 1991;9:1163–1172
  7. de Wit R, Stoter G, Sleijfer DT, et al. Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group. Br J Cancer. 1995;71:1311–1314
  8. Kaye SB, Mead GM, Fossa S, et al. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study. J Clin Oncol. 1998;16:692–701
  9. Motzer RJ, Mazumdar M, Bajorin DF, et al. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol. 1997;15:2546–2552
  10. Decatris MP, Wilkinson PM, Welch RS, et al. High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. Ann Oncol. 2000;11:427–434
  11. Broun ER, Nichols CR, Turns M, et al. Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support. Cancer. 1994;73:1716–1720
  12. Bhatia S, Abonour R, Porcu P, et al. High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol. 2000;18:3346–3351
  13. Beyer J, Kramar A, Mandanas R, et al. High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables. J Clin Oncol. 1996;14:2638–2645
  14. Broun ER, Nichols CR, Gize G, et al. Tandem high dose chemotherapy with autologous bone marrow transplantation for initial relapse of testicular germ cell cancer. Cancer. 1997;79:1605–1610
  15. Motzer RJ, Mazumdar M, Bosl GJ, et al. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity. J Clin Oncol. 1996;14:1098–1105
  16. Vaena DA, Abonour R, Einhorn LH. Long-term survival after high-dose salvage chemotherapy for germ cell malignancies with adverse prognostic variables. J Clin Oncol. 2003;21:4100–4104
  17. Statistics NCfH. National Hospital Discharge Survey for 1990 and 1991, in Branch HCS. Hyattsville, MD: U. S. Department of Health and Human Services, Public Health Service, Centers for Disease Control.
  18. Graves EJ. Detailed diagnoses and procedures, National Hospital Discharge Survey, 1989. Vital Health Stat. 1991;13:1–236
  19. Curtis RE, Rowlings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. N Engl J Med. 1997;336:897–904
  20. Silberman G, Crosse MG, Peterson EA, et al. Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med. 1994;331:1063–1067
  21. Kaplan E. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  22. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706
  23. Rosenbaum P, Rubin D. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983;70:41–55
  24. Rosenbaum P, Rubin D. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984;79:516–524
  25. Andersen PK, Klein JP, Zhang MJ. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18:1489–1500
  26. Mead GM. International consensus prognostic classification of metastatic germ cell tumours treated with cisplatinum based chemotherapy: final report of the International Germ Cell Cancer Collaborative Group (IGCCCG). Proc Am Soc Clin Oncol. 1995;
  27. Droz JP, Pico JL, Ghosn M, et al. Long-term survivors after salvage high dose chemotherapy with bone marrow rescue in refractory germ cell cancer. Eur J Cancer. 1991;27:831–835
  28. Schmoll HJ, Kollmannberger C, Metzner B, et al. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the german testicular cancer study group. J Clin Oncol. 2003;21:4083–4091
  29. Nichols CR, Tricot G, Williams SD, et al. Dose-intensive chemotherapy in refractory germ cell cancer—a phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation. J Clin Oncol. 1989;7:932–939
  30. Nichols CR, Andersen J, Lazarus HM, et al. High-dose carboplatin and etoposide with autologous bone marrow transplantation in refractory germ cell cancer: an Eastern Cooperative Oncology Group protocol. J Clin Oncol. 1992;10:558–563
  31. Pico JL, Rosti G, Kramar A, et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol. 2005;16:1152–1159
  32. Motzer RJ, Sheinfeld S. Poor-risk testicular cancer and high-dose chemotherapy. J Clin Oncol. 2003;21:4073–4074
  33. Kollmannsberger C, Beyer J, Liersch R, et al. Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol. 2004;22:108–114

PII: S1083-8791(07)00193-0

doi: 10.1016/j.bbmt.2007.02.013

Biology of Blood and Marrow Transplantation
Volume 13, Issue 7 , Pages 778-789 , July 2007

Article Tools

* Image Usage & Resolution